Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vaxcyte, Inc.

NASDAQ: PCVX · Life Sciences · 10 alerts · CIK 1649094

Share price
$61.61Close, Nov 16
Market cap
$9.75B
Shares outstanding
158.3MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vaxcyte, Inc. filings on SEC EDGAR ↗

8:01 AM ET 8-K
Clinical Trial Data

Vaxcyte Clinical Trial Data

Vaxcyte announced positive topline results from its OPUS-1 pivotal Phase 3 trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate for adults. The trial met all prespecified primary immunogenicity and safety endpoints, demonstrating noninferiority to Prevnar 20 and Capvaxive. These results will support a planned Biologics License Application (BLA) submission to the FDA in the first half of 2028.

Earnings call
Oct 5, 2026, 8:00 AM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.